Home › Diffuse Large B-Cell Lymphoma › Minnesota
Diffuse Large B-Cell Lymphoma clinical trials in Minnesota
15 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in Minnesota.
Cities in Minnesota
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- and 3 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06649812A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Mayo Clinic - Rochester, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06091865A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Mayo Clinic - Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07101328A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Mayo Clinic Rochester, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07188558Auto Stem Cell Transplant for Lymphoma Patients
- Masonic Cancer Center, University of Minnesota, Minneapolis
RecruitingPhase 2
Up to age 75 · All sexes · Updated Nov 4, 2026 · NCT03125642A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Mayo Clinic - Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07226843Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- University of Minnesota Medical Center, Minneapolis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06500273Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- Essentia Health Hibbing Clinic, Hibbing
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT05890352Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Mayo Clinic Health Systems-Mankato, Mankato
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06834373A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05006716Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Mayo Clinic Health Systems-Mankato, Mankato
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT03418038Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
- University of Minnesota/Masonic Cancer Center, Minneapolis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT06536049DALY II USA/ MB-CART2019.1 for DLBCL
- Mayo Clinic, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 26, 2024 · NCT06238648From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.